Rapid Autopsy Protocol for Patients with Small Cell Lung Cancer
S
Shadia Jalal, MD
Primary Investigator
Enrolling By Invitation
18-100 years
All
Phase
N/A
20 participants needed
3 Locations
Brief description of study
What is the purpose of this study?
This is pilot study to establish a rapid autopsy program in Small Cell Lung Cancer (SCLC) at the Indiana University Simon Comprehensive Cancer Center and outline the components necessary for tumor tissue collection. This proposal is a collaboration between scientists, lung cancer physicians, pathologists, and the IUSCCC Translational Research Core. The goal is to develop a multi-disciplinary rapid autopsy program at IUSCCC for patients who die and have a diagnosis of active small cell lung cancer
This is pilot study to establish a rapid autopsy program in Small Cell Lung Cancer (SCLC) at the Indiana University Simon Comprehensive Cancer Center and outline the components necessary for tumor tissue collection. This proposal is a collaboration between scientists, lung cancer physicians, pathologists, and the IUSCCC Translational Research Core. The goal is to develop a multi-disciplinary rapid autopsy program at IUSCCC for patients who die and have a diagnosis of active small cell lung cancer
THIS STUDY IS ENROLLING BY INVITATION ONLY - Consistent with most oncology trials, patients are not actively “recruited,” but are screened by their physician for appropriate clinical trial(s) at the time of their routine clinic visit. Occasionally, a patient may be a self-referral or physician referral, but are still screened for appropriate clinical trials at the time of their routine clinic visit. PI and staff may send copies of relevant consent forms to these patients to look over prior to actually consenting or enrolling them. This may take place at the patient's visit at which the consent is presented or the patient's next visit to the outpatient hematology/oncology clinic.
Interested in participating? For more information about this research study or other cancer-related clinical trials at IU Simon Comprehensive Cancer Center, please contact:
IU Clinical Trials Office
Email: iutrials@iu.edu
Phone: (317) 278-5632
Detailed description of study
What will happen during the study?
- Tumor tissue collected will be used for protein and gene analysis and RNA, whole exome sequencing in addition to the establishment of SCLC.
- This research is part of a discovery project in which biological and molecular markers of SCLC will be identified.Utilize tissue obtained from rapid autopsies to generate novel patient derived xenograft models and tumor cell lines, in addition to RNA, whole exome and whole genome sequencing, protein extraction to better understand the complex biology of SCLC and set up an infrastructure to develop relevant clinical models that will allow the development of better therapies.
Eligibility of study
You may be eligible for this study if you meet the following criteria:
- Conditions: Small Cell Lung Cancer
-
Age: Between 18 Years - 100 Years
-
Gender: All
Inclusion Criteria:
- ≥ 18 years old at the time of informed consent
- Written informed consent and HIPAA authorization for release of personal health information
- Active SCLC diagnosis
Updated on
01 Aug 2024.
Study ID: CTO-IUSCCC-0783, 13884
Please visit our main page to search for other studies you may be interested in.
If you need help finding a study or have any questions, please contact us at inhealth@iu.edu
